Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary

Obstetrics and Gynecology

Volumn 100, Issue 2, 2002, Pages 281-287

  Itamochi, Hiroaki ^a   Kigawa, Junzo ^a,e   Sugiyama, Toru ^b   Kikuchi, Yoshihiro ^c   Suzuki, Mitsuaki ^d   Terakawa, Naoki ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b KURUME UNIVERSITY   (Japan)

^c NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^d JICHI MEDICAL UNIVERSITY   (Japan)

^e TOTTORI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GLYCOPROTEIN P; KI 67 ANTIGEN; MULTIDRUG RESISTANCE PROTEIN; PLATINUM DERIVATIVE;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; LABELING INDEX; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SURVIVAL TIME;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DIVISION; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; CONFIDENCE INTERVALS; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARIECTOMY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0036338490     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(02)02040-9     Document Type: Article

References (34)

1. Ovarian clear cell adenocarcinoma
2. Clear cell carcinoma of the ovary: A study of 59 cases
3. Clear cell adenocarcinoma of the ovary: A clinical analysis and comparison with serous carcinoma
4. Clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease
5. Clinical characteristics of clear cell carcinoma of the ovary
6. Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy
7. Clinical characteristics of clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy
8. Cis-Diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells
9. Cellular pharmacology of cisplatin: Perspectives on mechanisms of acquired resistance
10. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis
11. Determinants of drug response in a cisplatin-resistant human lung cancer cell line
12. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin
13. Gamma-glutamyl cysteine synthetase up-regulates glutathione and multidrug resistance associated protein in patients with chemoresistant epithelial ovarian cancer
14. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance
15. Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies
16. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer
17. Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma
18. DNA flow cytometry and response to preoperative chemotherapy for primary breast cancer
19. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67
20. Expression of P-glycoprotein in human placenta: Relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene
21. Drug resistance associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma
22. Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma
23. Immunophenotype of ovarian cancer as predictor of clinical outcome: Evaluation at primary surgery and second-look procedure
24. Amplification of the mdr1-gene is uncommon in recurrent ovarian carcinomas
25. Molecular mechanisms of multidrug resistance in cancer chemotherapy
26. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma
27. The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer
28. Multidrug resistance protein in recurrent breast cancer
29. Glutathione S-transferase-π expression and glutathione concentration in ovarian carcinoma before and after chemotherapy
30. Activation of AP-1 and of a nuclear redox factor, Ref-1, in the response of HT29 colon cancer cells to hypoxia
31. Intracellular glutathione levels regulate Fos/Jun induction and activation of glutathione S-transferase gene expression
32. Confluence-dependent resistance in human colon cancer cells: Role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells
33. Predictive value of proliferative cellular nuclear antigen (PCNA) and Ki-67 antigen in advanced stage serous papilliferous ovarian cancer